



Hematological Malignancies

Guest Editor:

Prof. Dr. Maria Moschovi

Hematology/Oncology Unit, 1st
Department of Pediatrics, "Agia
Sophia" Children's Hospital,
School of Medicine, National and
Kapodistrian University of
Athens, 10679 Athens, Greece

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editor

Chronic myelogenous leukemia is the first hematological malignancy for which a drug was devised against the molecular hallmark of the disease. Juvenile myelomonocytic leukemia constitutes an archetype of genetic predisposition to hematological malignancy with specific correlations of genotype–phenotype. Genetic predisposition to myeloid neoplasms provides an additional basis of hematological malignancy classification. Histiocytic syndromes are caused by ‘druggable’ mutations in the RAS-MAPK pathway. Genetic alterations in key molecules of lymphopoiesis are the basis of prognostic stratification in acute lymphoblastic leukemia. Rare subtypes of lymphoma are also carried by specific molecular abnormalities such as anaplastic lymphoma and ALK mutations.

The aim of this issue is to offer an overview of molecular targets in pediatric hematological malignancies and their therapeutic counterpart. Several neoplasms should be covered, and we invite authors to choose topics well beyond acute leukemia.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI